Results 11 to 20 of about 9,011 (201)

Levosimendan in Cardiac Arrest (LeiCA): Protocol for a Randomized, Double-Blind, Phase II Clinical Trial. [PDF]

Acta Anaesthesiol Scand
ABSTRACT Background Despite developments in advanced life support, outcomes after out‐of‐hospital cardiac arrest (OHCA) remain poor. Levosimendan, a calcium‐sensitizing inodilator commonly used in heart failure, has shown beneficial effects in several experimental models and anecdotal clinical cases of cardiac arrest. The Levosimendan in Cardiac Arrest
Rysz S, Flam B, Hedberg M, Galmén K, Mårtensson J, Djärv T, Jonsson Fagerlund M.   +6 more
europepmc   +2 more sources

Successful Use of Levosimendan in Four Critically Ill Neonates With Pulmonary Hypertension: A Case Series. [PDF]

Pediatr Pulmonol
Pediatric Pulmonology, Volume 60, Issue 12, December 2025.
Kantzavelou A, Chatzigiannis N, Baltogianni M, Atzemoglou N, Giapros V.   +4 more
europepmc   +2 more sources

Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?

European Radiology Experimental, 2021
Background We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. Methods Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8).
Irmak Durur-Subasi, Duygu Kose, Muhammed Yayla, Busra Sirin, Adem Karaman, Ilknur Calik, Fatih Alper   +6 more
doaj   +1 more source

Potentiating Cerebral Perfusion Normalizes Glymphatic Dynamics in Systemic Inflammation. [PDF]

Adv Sci (Weinh)
LPS‐induced systemic inflammation increases glymphatic influx but delays cervical lymphatic drainage, accompanied by AQP4 depolarization and impaired glymphatic clearance. Enhancing cerebral blood flow via the inotropic agent levosimendan effectively restored AQP4 polarization, improving glymphatic flux and amyloid‐β clearance.
Zhao R, Sun B, Wei P, Sun Y, He Q, Zhang K, Lu J, Zhu S, Yang Y, Guo Z.   +9 more
europepmc   +2 more sources

Influence of timing of Levosimendan administration on outcomes in cardiac surgery

Frontiers in Cardiovascular Medicine, 2023
PurposeThough a subgroup analysis has shown improved survival for patients suffering severely reduced ventricular function undergoing coronary artery bypass grafting, RCTs were not able to demonstrate overall beneficial effects of perioperative ...
Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Christian Berger, Liubov Penkova, Herko Grubitzsch, Bernhard Haller, Alexander Meyer, Alexander Meyer, Matthias Heringlake, Michael Sander, Joachim M. Erb, Felix Balzer, Sascha Treskatsch   +13 more
doaj   +1 more source

Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy

Journal of Cardiothoracic Surgery, 2020
Background Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In
Juan José Jiménez-Rivera, Andrea Álvarez-Castillo, Jorge Ferrer-Rodríguez, José Luis Iribarren-Sarrías, Martín Jesús García-González, Pablo Jorge-Pérez, Juan Lacalzada-Almeida, Rosalía Pérez-Hernández, Javier Montoto-López, Rafael Martínez-Sanz   +9 more
doaj   +1 more source

The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses

Biomedicines, 2023
The calcium sensitizer levosimendan is used for the treatment of acute decompensated heart failure. A small portion (4–7%) of levosimendan is metabolized to the pharmacologically active metabolite OR-1896 via the inactive intermediate OR-1855.
Hannah Kipka, Rebecca Schaflinger, Roland Tomasi, Kristin Pogoda, Hanna Mannell   +4 more
doaj   +1 more source

Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock

Frontiers in Cardiovascular Medicine, 2022
BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest.
Yu-Wen Chen, Wei-Chieh Lee, Wei-Chieh Lee, Po-Jui Wu, Hsiu-Yu Fang, Yen-Nan Fang, Huang-Chung Chen, Meng-Shen Tong, Pei-Hsun Sung, Chieh-Ho Lee, Wen-Jung Chung   +10 more
doaj   +1 more source

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure

BMC Anesthesiology, 2011
Background Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room.
Suominen Pertti K
doaj   +1 more source

Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

Critical Care, 2020
Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock.
Enrique Guilherme, Matthias Jacquet-Lagrèze, Matteo Pozzi, Felix Achana, Xavier Armoiry, Jean-Luc Fellahi   +5 more
doaj   +1 more source